SCHEMBL7147149

SCHEMBL7147149

COc1cccc(NS(=O)(=O)CCCCSc2nc3cc4c(cc3s2)OCO4)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.43
KDM4E B2RXH2 6/20 0.43
LMNA P02545 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 3/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43
THRB P10828 3/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 2/20 0.40
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
STAT1 P42224 1/20 0.38
PRNP P04156 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153034 0.97 MAPT (0.44) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7154996 0.94 MAPT (0.46) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7149163 0.91 MAPT (0.46) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7153204 0.89 ALDH1A1 (0.41) MAPTLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL7151115 0.88 MAPT (0.46) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7152202 0.87 MAPT (0.49) MAPTLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL7151043 0.86 ALDH1A1 (0.42) MAPTLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL7148433 0.85 KDM4E (0.46) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7155045 0.85 ALDH1A1 (0.50) MAPTKDM4ELMNASMN1; SMN2KMT2A
SCHEMBL7153984 0.84 LMNA (0.46) MAPTLMNASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885KDM4E 3463/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.